Want to see NTHI full AI Analyst Report?
NTHI Stock Chart & Stats
$3.43
-$0.04(-1.02%)
At close: 4:00 PM EDT
$3.43
-$0.04(-1.02%)
Day’s Range― - ―
52-Week Range$3.01 - $12.99
Previous CloseN/A
Volume13.97K
Average Volume (3M)103.40K
Market Cap
$90.50M
Enterprise Value$96.38M
Total Cash (Recent Filing)$138.60K
Total Debt (Recent Filing)$346.05K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 25, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding25,931,866
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.01K
Enterprise Value/Ebitda-2.74
Forecast
1Y Price Target
$16.00Price Target Upside366.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
International Regulatory PathwaysUAE IND clearance for NEO212 creates parallel, non‑U.S. development options and can shorten timelines by enabling additional Phase 2 work outside the U.S. This diversifies regulatory risk, supports faster data generation, and can catalyze regulatory dialogue and potential regional partnerships over the next several quarters.
Intellectual Property ProtectionA globally licensed patent estate through 2038 provides a structural barrier to entry for competitors, protecting NeOnc's chemo agents and delivery methods. If lead candidates advance, this exclusivity supports long‑term commercialization economics and makes the programs more attractive to partners or acquirers.
Near‑term Funding And Runway ExtensionThe $10M PIPE commitment plus an undrawn $10M credit line materially extends near‑term runway, lowering immediate liquidity risk and enabling completion of enrolled trials and key readouts. This funding window supports execution of clinical milestones that determine longer‑term value, reducing the urgency of near‑term dilutive raises.
Bears Say
Zero Revenue And Heavy Cash BurnThe company has no trailing revenue and sustained negative operating and free cash flow (~-$21.7M TTM), producing recurring cash deficits. Over time this structural cash burn forces dependence on external capital, constrains strategic optionality, and increases execution risk if financing terms deteriorate or markets tighten.
Ongoing Dilution And Financing TermsFrequent private financings, convertible preferred with discounted conversion features, and warrants suggest continued dilution risk. Structurally, reliance on dilutive capital can misalign incentives, dilute incumbent shareholders, and raise the cost of future raises, making long‑term capital planning and retention of investor support more challenging.
Early‑Stage Pipeline And Limited Operational ScaleThe company remains pre‑commercial with no revenue and a small operating base (5 employees). Sustaining multiple international trials and later commercial activities requires scaling capabilities and higher fixed costs. This structural gap increases execution risk, as successful clinical outcomes must precede meaningful revenue and organizational expansion.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $3.00 and its highest was $12.99 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $90.50M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
NeOnc Technologies Holdings, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 20 days.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Undervalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate is -0.12.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 25,931,866 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (366.47% Upside)
$16.00 (366.47% Upside)
Insider Transactions
Bought Shares
Worth $41.5K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.55%
Trailing 12-Months
Company Description
NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
NTHI Stock 12 Month Forecast
Average Price Target
$16.00
▲(366.47% Upside)
Technical Analysis
Ownership Overview
31.33% Insiders
1.25% Mutual Funds
0.76% Other Institutional Investors
64.71% Public Companies and
Individual Investors